Analyst Reco. Exact Sciences Corporation

Equities

EXAS

US30063P1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
54.08 ^USD	+1.10%		+4.10%	-26.90%

May. 23	U.S. FDA advisers back approval for Guardant's cancer test	RE
May. 21	Exact Sciences Says Court Allows Patent Lawsuit Against Geneoscopy to Proceed	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Benchmark Upgrades Exact Sciences to Buy From Hold, Sets Price Target at $91	Jan. 02	MT
Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating	Nov. 03	MT
BofA Securities Cuts Price Target on Exact Sciences to $88 From $110, Maintains Buy Rating	23-10-20	MT
Piper Sandler Upgrades Exact Sciences to Overweight From Neutral, Price Target is $90	23-10-10	MT
Bernstein Starts Exact Sciences With Outperform Rating	23-09-28	MT
Baird Adjusts Price Target on Exact Sciences to $121 From $99, Maintains Outperform Rating	23-08-02	MT
Benchmark Downgrades Exact Sciences to Hold From Buy	23-08-02	MT
Credit Suisse Adjusts Exact Sciences' Price Target to $90 From $75, Keeps Neutral Rating	23-08-02	MT
Goldman Sachs Adjusts Price Target on Exact Sciences to $110 From $85, Maintains Buy Rating	23-07-21	MT
UBS Raises Exact Sciences' Price Target to $99 From $73, Maintains Neutral Rating	23-06-27	MT
Canaccord Genuity Raises Price Target on Exact Sciences to $115 From $92, Maintains Buy Rating	23-06-23	MT
ANALYST RECOMMENDATIONS : BAE Systems, Berkeley, Burberry, Reinsurance Group, Tesla...	23-06-23
Citigroup Adjusts Price Target on Exact Sciences to $130 From $100, Keeps Buy Rating	23-06-22	MT
Exact Sciences says its new colon cancer test shows 30% lower false positive rate	23-06-20	RE
Jefferies Raises Exact Sciences' Price Target to $100 From $82, Maintains Buy Rating	23-06-07	MT
Citigroup Adjusts Price Target on Exact Sciences to $100 From $90, Maintains Buy Rating	23-05-11	MT
Baird Adjusts Price Target on Exact Sciences to $99 From $92, Maintains Outperform Rating	23-05-10	MT
BofA Adjusts Price Target on Exact Sciences to $88 From $80, Keeps Buy Rating	23-05-10	MT
Credit Suisse Raises Exact Sciences' PT to $75 From $70, Notes Broad-based Momentum, Guide Upgrade; Keeps Neutral Rating	23-05-10	MT
Craig Hallum Upgrades Exact Sciences to Buy From Hold, Raises Price Target to $85 From $55	23-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Exact Sciences Corporation

Equities

EXAS

US30063P1057

Analyst Reco.

Filters